Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Inhaled liposomal IL-2 well tolerated in patients with lung metastases

Oct. 31, 2000

Zevalin effective and safe in refractory, heavily pretreated NHL patients

Oct. 30, 2000

Boehringer Ingelheim presents new series of inhibitors of signal transduction

Oct. 30, 2000

Patient enrollment begins in phase I trial of Cotara for colorectal cancer

Oct. 30, 2000

Substituted aza-oxindoles which inhibit protein tyrosine or serine/threonine kinases

Oct. 30, 2000

Antisoma licenses thioplatin from German cancer center

Oct. 30, 2000

Chemotherapeutic potential of competitive glyoxalase I inhibitor evaluated in tumor-bearing mice

Oct. 30, 2000

Alza's Caelyx approved in E.U. for advanced ovarian cancer

Oct. 27, 2000

MacroMed's OncoGel enters phase I

Oct. 27, 2000

Triazine derivative inhibits angiogenesis in vivo

Oct. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...